RxDoctor Payments Data

Daniela Garcia-Cruz

Physician Assistant · Louisville, KYNPI 1952961831

Payments from drug & device makers

$2,100in general payments, 2019–2025

Across 73 payments — averaging $28.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Idorsia Pharmaceuticals US Inc$192
  • Johnson & Johnson$142
  • Indivior Inc.$141
  • Alkermes, Inc.$101
  • USWM, LLC$75
  • plus $161 from 5 others

What the payments were for

  • Food & beverage$2,05698%
  • Education$442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,100 in reported general payments places this provider in the 80th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$32,463
Medicare patients
70
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate33$111,608
VraylarCariprazine Hcl56$78,894
RexultiBrexpiprazole16$25,273
Lurasidone Hcl42$11,354
Divalproex Sodium ErDivalproex Sodium36$4,753
Aripiprazole85$4,478
Paliperidone ErPaliperidone36$4,352
Lamotrigine ErLamotrigine14$3,767
Carbamazepine ErCarbamazepine24$3,130
Clozapine26$2,229
Divalproex Sodium33$1,881
Ziprasidone Hcl13$1,644
Gabapentin75$1,428
Ramelteon16$1,276
Trazodone Hcl90$1,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$142$111,60833 claims
AbbVieVraylar$1,288$78,89456 claims
Otsuka America Pharmaceutical, Inc.Rexulti$25$25,27316 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$35$94415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →